Seeking Alpha

Drug developer Aastrom (ASTM +5.2%) is trading higher after saying the 12-month follow-up data...

Drug developer Aastrom (ASTM +5.2%) is trading higher after saying the 12-month follow-up data from clinical trials for its drug ixmyelocel-T showed that treatment was well-tolerated, and efficacy observations were consistent with improved heart function.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)